Federal Preemption Defense (Pharma/Device)

Federal preemption in pharmaceutical and medical device mass torts is the doctrine, grounded in the Supremacy Clause, under which federal regulatory requirements displace state-law tort claims that would impose additional or conflicting obligations on a manufacturer. The doctrine operates differently across product categories: for medical devices that received premarket approval from the FDA, Riegel v. Medtronic (2008) held that state-law claims imposing requirements different from or in addition to federal requirements are expressly preempted under 21 U.S.C. § 360k; for brand-name prescription drugs, Wyeth v. Levine (2009) held that state-law failure-to-warn claims are generally not preempted because federal law permits manufacturers to unilaterally strengthen a warning label without prior FDA approval through the changes-being-effected process; and for generic drugs, PLIVA v. Mensing (2011) held that failure-to-warn claims are preempted because federal law requires generic labeling to match the brand label exactly. A separate implied preemption doctrine under Buckman Co. v. Plaintiffs' Legal Committee (2001) bars state-law claims premised on an alleged fraud on the FDA, reasoning that policing the integrity of FDA submissions is a matter exclusively for federal enforcement. Preemption exposure therefore varies dramatically depending on whether the product is a premarket-approved device, a brand drug, or a generic drug.

Preemption is frequently case-dispositive and is typically litigated and resolved at the pleading or summary judgment stage, well before any factual development of causation or damages, making it one of the earliest and highest-value diligence items in any pharma or device mass tort.

Funders must classify the product at issue before advancing capital, since a docket built around generic-drug defendants faces materially different preemption exposure than an equivalent docket against the brand manufacturer, and misclassifying this exposure is one of the most common underwriting errors in pharmaceutical litigation finance.